Relay Therapeutics CEO Sanjiv Patel sells $872,401 company stock

On October 7, 2026, Sanjiv Patel, CEO of Relay Therapeutics, sold 48,199 shares of company stock worth $872,401. The sale took place between $17.87 and $18.46 per share, with an average price of $18.10 per share. This transaction was made according to a pre-established Rule 10b5-1 trading plan Patel set up on October 30, 2025. The sale came after a 185% price increase for the stock over the past year, despite a recent pullback from its 52-week high of $21.27.

Currently, Patel personally owns 471,301 shares directly and has 199,548 shares indirectly held by the Patel Family Irrevocable Trust of 2019 and 687,355 shares indirectly held by The SSP Irrevocable Trust of 2020. Patel explicitly disclaims any beneficial ownership of the indirectly held shares, which are held for his family members' benefit in irrevocable trusts overseen by independent trustees.

Recent financial reports from Relay Therapeutics revealed a net loss of $0.41 per share for the second quarter, surpassing H.C. Wainwright's estimate of $0.37 per share. The company's research and development costs amounted to $76.5 million, while selling, general, and administrative expenses totaled $14.7 million, both exceeding expectations.

In response, H.C. Wainwright raised its price target to $29 and maintained a Buy rating, while Citizens increased its price target to $26. Guggenheim reiterated a Buy rating with a $26 target, focusing on Relay's progress in breast cancer treatment development. Canaccord initiated coverage with a Buy rating and a $29 price target, highlighting the company's lead asset, zovegalisib.

JPMorgan initiated coverage with an Overweight rating and a $28 price target, emphasizing zovegalisib's growth potential. These actions from various analysts reflect a generally positive outlook on Relay Therapeutics' future prospects.